^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DS-3939

    i
    Other names: DS-3939, DS-3939a, GT-00A ADC, DS3939, DS 3939, DS3939a, DS 3939a, GT00A ADC, GT 00A ADC
    Associations

    News

    Trials
    Company:
    Daiichi Sankyo, Glycotope
    Drug class:
    Topoisomerase I inhibitor, TA-MUC1-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    3d
    DS-3939a: A TA-MUC1-directed Antibody-Drug Conjugate with Broad Anti-Tumor Activity. (PubMed, Mol Cancer Ther)
    Moreover, DS-3939a elicited strong tumor regression in several xenograft models even following treatment with other cytotoxic ADCs, likely through its efficient payload delivery. Overall, these data provide evidence for the potential utility of DS-3939a for the treatment of TA-MUC1-expressing tumors and support the rationale for the ongoing phase I/II clinical study (NCT05875168).
    Journal
    |
    MUC1 (Mucin 1)
    |
    DS-3939
    almost2years
    First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=430, Recruiting, Daiichi Sankyo, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    MUC1 (Mucin 1)
    |
    MUC1 expression
    |
    DS-3939
    2years
    First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=430, Not yet recruiting, Daiichi Sankyo, Inc.
    New P1/2 trial • Metastases
    |
    MUC1 (Mucin 1)
    |
    MUC1 expression
    |
    DS-3939